These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
690 related articles for article (PubMed ID: 3130683)
1. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Filardi LS; Brener Z Trans R Soc Trop Med Hyg; 1987; 81(5):755-9. PubMed ID: 3130683 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of chemotherapy with benznidazole and nifurtimox in mice infected with Trypanosoma cruzi strains of different types. Andrade SG; Magalhães JB; Pontes AL Bull World Health Organ; 1985; 63(4):721-6. PubMed ID: 3936634 [TBL] [Abstract][Full Text] [Related]
3. [Isoenzymatic pattern of Trypanosoma cruzi Y strain after specific chemotherapy]. Silva RC; Santiago CM; Pontes AL; Andrade SG Mem Inst Oswaldo Cruz; 1989; 84(1):81-6. PubMed ID: 2108307 [TBL] [Abstract][Full Text] [Related]
4. [Treatment of Chagas' disease]. Apt W Rev Med Chil; 1985 Feb; 113(2):162-6. PubMed ID: 3936147 [No Abstract] [Full Text] [Related]
5. Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection). Vallejo M; Reyes PP; Martinez Garcia M; Gonzalez Garay AG Cochrane Database Syst Rev; 2020 Dec; 12(12):CD004102. PubMed ID: 33305846 [TBL] [Abstract][Full Text] [Related]
6. Trypanosoma cruzi: chemotherapy with benznidazole in mice inoculated with strains from Paraná state and from different endemic areas of Brazil. Toledo MJ; Guilherme AL; da Silva JC; de Gasperi MV; Mendes AP; Gomes ML; de Araújo SM Rev Inst Med Trop Sao Paulo; 1997; 39(5):283-90. PubMed ID: 9661307 [TBL] [Abstract][Full Text] [Related]
7. Current drug therapy and pharmaceutical challenges for Chagas disease. Bermudez J; Davies C; Simonazzi A; Real JP; Palma S Acta Trop; 2016 Apr; 156():1-16. PubMed ID: 26747009 [TBL] [Abstract][Full Text] [Related]
8. Trypanosoma cruzi genetic diversity: Something new for something known about Chagas disease manifestations, serodiagnosis and drug sensitivity. Zingales B Acta Trop; 2018 Aug; 184():38-52. PubMed ID: 28941731 [TBL] [Abstract][Full Text] [Related]
9. The efficacy of a novel compound, (e)-1-(4'-bromo-4-biphenylyl)-1-(4-chlorophenyl)-3-dimethylaminoprop-1-ene against Trypanosoma cruzi in mice. Barrett PA; Beveridge E; Bull D; Caldwell IC; Islip PJ; Neal RA; Woods NC Experientia; 1982 Mar; 38(3):338-9. PubMed ID: 6804255 [TBL] [Abstract][Full Text] [Related]
10. Drug discovery for chagas disease: A viewpoint. Kratz JM Acta Trop; 2019 Oct; 198():105107. PubMed ID: 31351074 [TBL] [Abstract][Full Text] [Related]
11. 5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies. Cabrera E; Murguiondo MG; Arias MG; Arredondo C; Pintos C; Aguirre G; Fernández M; Basmadjián Y; Rosa R; Pacheco JP; Raymondo S; Di Maio R; González M; Cerecetto H Eur J Med Chem; 2009 Oct; 44(10):3909-14. PubMed ID: 19446929 [TBL] [Abstract][Full Text] [Related]
12. Molecular and biological characterization of a highly pathogenic Trypanosoma cruzi strain isolated from a patient with congenital infection. Gulin JEN; Bisio M; Rocco DM; Altcheh J; Solana ME; García-Bournissen F Exp Parasitol; 2018 Mar; 186():50-58. PubMed ID: 29448038 [TBL] [Abstract][Full Text] [Related]
13. Response to chemotherapy with benznidazole of clones isolated from the 21SF strain of Trypanosoma cruzi (biodeme Type II, Trypanosoma cruzi II). Campos RF; Guerreiro ML; Sobral Kde S; Lima Rde C; Andrade SG Rev Soc Bras Med Trop; 2005; 38(2):142-6. PubMed ID: 15821788 [TBL] [Abstract][Full Text] [Related]
14. [Etiological treatment of Chagas' disease]. Rassi A Arq Bras Cardiol; 1982 Apr; 38(4):277-81. PubMed ID: 6820273 [No Abstract] [Full Text] [Related]
15. [Etiologic therapy of Chagas' disease]. Boainain E; Rassi A Arq Bras Cardiol; 1979 Jun; 32(6):395-9. PubMed ID: 116629 [No Abstract] [Full Text] [Related]
16. Effect of length of treatment with Bayer 2502 on isolation of Trypanosoma cruzi and resistance to challenge in the mouse. Morrow DT; Wescott RB; Davis WC Am J Trop Med Hyg; 1977 May; 26(3):382-6. PubMed ID: 405877 [TBL] [Abstract][Full Text] [Related]
17. The effect of benznidazole dose among the efficacy outcome in the murine animal model. A quantitative integration of the literature. Molina I; Perin L; Aviles AS; de Abreu Vieira PM; da Silva Fonseca K; Cunha LM; Carneiro CM Acta Trop; 2020 Jan; 201():105218. PubMed ID: 31610148 [TBL] [Abstract][Full Text] [Related]
18. Comparative studies of drug susceptibility of five strains of Trypanosoma cruzi in vivo and in vitro. Neal RA; van Bueren J Trans R Soc Trop Med Hyg; 1988; 82(5):709-14. PubMed ID: 3075357 [TBL] [Abstract][Full Text] [Related]
19. In vivo susceptibility to benznidazole of Trypanosoma cruzi strains from the western Brazilian Amazon. Teston AP; Monteiro WM; Reis D; Bossolani GD; Gomes ML; de Araújo SM; Bahia MT; Barbosa MG; Toledo MJ Trop Med Int Health; 2013 Jan; 18(1):85-95. PubMed ID: 23130989 [TBL] [Abstract][Full Text] [Related]
20. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial. Villar JC; Herrera VM; Pérez Carreño JG; Váquiro Herrera E; Castellanos Domínguez YZ; Vásquez SM; Cucunubá ZM; Prado NG; Hernández Y Trials; 2019 Jul; 20(1):431. PubMed ID: 31307503 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]